<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2008-03-19" updated="2019-12-02">
  <drugbank-id primary="true">DB06568</drugbank-id>
  <name>alpha-Hydroxy glycineamide</name>
  <description>Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid formation. It also has an effect on viral gp160 envelope protein. [A31692]</description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31690</ref-id>
        <pubmed-id>18644965</pubmed-id>
        <citation>Abdurahman S, Vegvari A, Youssefi M, Levi M, Hoglund S, Andersson E, Horal P, Svennerholm B, Balzarini J, Vahlne A: Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity. Antimicrob Agents Chemother. 2008 Oct;52(10):3737-44. doi: 10.1128/AAC.00265-08.  Epub 2008 Jul 21.</citation>
      </article>
      <article>
        <ref-id>A31691</ref-id>
        <pubmed-id>19356241</pubmed-id>
        <citation>Abdurahman S, Vegvari A, Levi M, Hoglund S, Hogberg M, Tong W, Romero I, Balzarini J, Vahlne A: Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology. Retrovirology. 2009 Apr 8;6:34. doi: 10.1186/1742-4690-6-34.</citation>
      </article>
      <article>
        <ref-id>A31692</ref-id>
        <pubmed-id>24780097</pubmed-id>
        <citation>Youssefi M, Vahlne A: Anti-human immunodeficiency virus type 1 agent alpha-hydroxy glycineamide enters the target cells via a mechanism of passive diffusion. J Pharm Pharmacol. 2014 Oct;66(10):1388-93. doi: 10.1111/jphp.12269. Epub 2014 Apr 29.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in HIV infection.</indication>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">aHGA</synonym>
    <synonym language="english" coder="">alfaHGA</synonym>
    <synonym language="english" coder="">alpha-HGA</synonym>
    <synonym language="english" coder="">alpha-hydroxy-glycineamide</synonym>
    <synonym language="english" coder="">alphaHGA</synonym>
    <synonym language="english" coder="">αHGA</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers/>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>